Analysis of the effect of intravitreal methotrexate for refractory intraocular inflammation

Analysis of the effect of intravitreal methotrexate for refractory intraocular inflammation - Analysis of the effect of intravitreal methotrexate for refractory intraocular inflammation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013595

Enrollment

Registered

2014-06-01

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory intraocular inflammation

Interventions

Follow up duration:6 month Intravitreal injection of methotrexate 400ug/100ul is administered once and repeated for recurrence case(interval more than one month)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patient of refractory intraocular inflammation 2)written informed consent 3)patient who was judged by doctor to be able to receive the protocol therapy

Exclusion criteria

Exclusion criteria: 1)history of serious adverse reaction by methotrexate 2)active infectious disease of eye 3)patient who was judged by doctor not to be able to receive drug

Design outcomes

Primary

Measure	Time frame
To evaluate improvement of intraocular inflammation after treatment for 6 months	—

Secondary

Measure	Time frame
Adverse event	—

Countries

Japan

Contacts

Public ContactMariko Egawa

Institute of Health Biosiences, The University of Tokushima Graduate School Ophthalmology

egawa.m@tokushima-u.ac.jp088-633-7163

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026